Fig. 3: Outcomes in non-completers.

Mean change in visual acuity in non-completers from baseline (base) to their last observed visit (point) in eyes that started vascular endothelial growth factor (VEGF) inhibitor treatments for (A) neovascular age-related macular degeneration (nAMD), (B) diabetic macular oedema (DMO), (C) Branch retinal vein occlusion (BRVO), (D) Central retinal vein occlusion (CRVO) and (E) Hemi-retinal vein occlusion (HRVO). Outcomes are shown by the year of treatment initiation.